Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post-Marketing Studies For All Products Endorsed By Drug Safety Expert

This article was originally published in The Pink Sheet Daily

Executive Summary

A mechanism is needed for post-marketing testing of all new drugs, safety expert Gross says during a Drug & Device Dialogue audio conference on the COX-2 advisory committee meeting. FDA “needs more tools” to protect public health, consumer rep Levin argues.
Advertisement

Related Content

Drug Safety To Be Topic Of Senate Health Hearings March 1 & 3
Drug Safety To Be Topic Of Senate Health Hearings March 1 & 3
COX-2 Cardio Risk Is Class Effect, But Varies By Drug And Dose, Cmte. Says
COX-2 Inhibitors Contraindicated For Heart Disease Patients In Europe
FDA Drug Safety Reform Must Come From Outside Agency – Sen. Grassley
FDA Drug Safety Oversight Board Will Include VA, Other Agencies

Topics

Advertisement
UsernamePublicRestriction

Register

PS061621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel